MINIREVIEWS

521 Role of argon plasma coagulation in treatment of esophageal varices

528 Clinical features and potential mechanism of coronavirus disease 2019-associated liver injury
Han MW, Wang M, Xu MY, Qi WP, Wang P, Xi D

ORIGINAL ARTICLE

Retrospective Study

540 Circulating immune parameters-based nomogram for predicting malignancy in laryngeal neoplasm
Chen M, Fang Y, Yang Y, He PJ, Cheng L, Wu HT

552 Role of ammonia in predicting the outcome of patients with acute-on-chronic liver failure
Chiriac S, Stanciu C, Cojocariu C, Singeap AM, Sfarti C, Cuciureanu T, Girleanu I, Igna RA, Trifan A

565 Impact of different stereoisomers of inositol on insulin sensitivity of gestational diabetes mellitus patients
He J, Zhang YL, Wang LP, Liu XC

Observational Study

573 Fascial space odontogenic infections: Ultrasonography as an alternative to magnetic resonance imaging

SYSTEMATIC REVIEWS

581 Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
Xu YQ, Long X, Han M, Huang MQ, Lu JF, Sun XD, Han W

CASE REPORT

602 Delayed cardiac tamponade diagnosed by point-of-care ultrasound in a neonate after peripherally inserted central catheter placement: A case report
Cui Y, Liu K, Luan L, Liang P

607 Facial microcystic adnexal carcinoma — treatment with a “jigsaw puzzle” advancement flap and immediate esthetic reconstruction: A case report
Xiao YD, Zhang MZ, Zeng A

614 Nephrotic syndrome in syngeneic hematopoietic stem cell transplantation recipients: A case report
Bai MC, Wu JJ, Miao KR, Zhu JF, Mao HJ
Contents

World Journal of Clinical Cases

Thrice Monthly Volume 9 Number 3 January 26, 2021

623 Compound heterozygous mutations in the neuraminidase 1 gene in type 1 sialidosis: A case report and review of literature
Cao LX, Liu Y, Song ZJ, Zhang BR, Long WY, Zhao GH

632 Dynamic biomechanical effect of lower body positive pressure treadmill training for hemiplegic gait rehabilitation after stroke: A case report
Tang HF, Yang B, Lin Q, Liang JJ, Mou ZW

639 Right-heart contrast echocardiography reveals missed patent ductus arteriosus in a postpartum woman with pulmonary embolism: A case report
Chen JL, Mei DE, Yu CG, Zhao ZY

644 Treatment of cervical spine metastasis with minimally invasive cervical spondylectomy: A case report and literature review
He LM, Ma X, Chen C, Zhang HY

651 Successful treatment of pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii with multi-route tigecycline: A case report
Li W, Li DD, Yin B, Lin DD, Sheng HS, Zhang N

659 Radical resection of hepatic polycystic echinococcosis complicated with hepatocellular carcinoma: A case report
Kalifu B, Meng Y, Maimaitiiniyati Y, Ma ZG, Tian GL, Wang JG, Chen X

666 Pleural lump after paragonimiasis treated by thoracoscopy: A case report
Xie Y, Luo YR, Chen M, Xie YM, Sun CY, Chen Q

672 Deep vein thrombosis in patient with left-sided inferior vena cava draining into the hemiazygos vein: A case report
Zhang L, Guan WK

677 Recurrent Takotsubo cardiomyopathy triggered by emotionally stressful events: A case report
Wu HY, Cheng G, Liang L, Cao YW

685 Oral and perioral herpes simplex virus infection type I in a five-month-old infant: A case report
Aloyouny AY, Albagieh HN, Al-Serwi RH

690 Nasal septal foreign body as a complication of dental root canal therapy: A case report
Du XW, Zhang JB, Xiao SF

697 Coinheritance of OLFM2 and SIX6 variants in a Chinese family with juvenile-onset primary open-angle glaucoma: A case report
Yang X, Sun NN, Zhao ZN, He SX, Zhang M, Zhang DD, Yu XW, Zhang JM, Fan ZG

707 Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in a 77-year-old man: A case report
Xu ZG, Li WL, Wang X, Zhang SY, Zhang YW, Wei X, Li CD, Zeng P, Luan SD
Contents

714 Clinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report

722 Severe skeletal bimaxillary protrusion treated with micro-implants and a self-made four-curvature torquing auxiliary: A case report

736 Cystic duct dilation through endoscopic retrograde cholangiopancreatography for treatment of gallstones and choledocholithiasis: Six case reports and review of literature
He YG, Gao MF, Li J, Peng XH, Tang YC, Huang XB, Li YM

748 Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease—can we decrease the risk? Two case reports and review of literature
Gładys A, Kozak S, Wdowiak K, Winder M, Chudek J

758 Restenosis of a drug eluting stent on the previous bioresorbable vascular scaffold successfully treated with a drug-coated balloon: A case report
ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Dr. Marcelo A F Ribeiro Jr. is Full Professor of Surgery at Pontifical Catholic University – PUC Sorocaba – General and Trauma Surgery, and Professor of the Post-Graduation Program in Surgery, IAMSPE São Paulo (Brazil). He serves as Member and Fellow of the Brazilian College of Surgeons, Brazilian College of Digestive Surgery, Brazilian Trauma Society (General Secretary), American College of Surgeons, American Association for the Surgery of Trauma, Eastern Association for the Surgery of Trauma, and Pan-American Trauma Society (being Chairman of the Education Committee and Member of the Board). (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJCC* as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The *WJCC*’s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ji-Hong Liu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

*World Journal of Clinical Cases*

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Dennis A Bloomfield, Sandro Vento, Bao-gan Peng

EDITORIAL BOARD MEMBERS

https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE

January 26, 2021

COPYRIGHT

© 2021 Baishideng Publishing Group Inc
Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease—can we decrease the risk? Two case reports and review of literature

Aleksandra Gładyś, Sylwia Kozak, Kamil Wdowiak, Mateusz Winder, Jerzy Chudek

BACKGROUND
Post-transplant lymphoproliferative disease (PTLD) is a heterogeneous group of diseases that develop after solid organ and hematopoietic stem cells transplantation related to intensive immunosuppression regimen, T-cell depletion and Epstein-Barr virus infection. Despite the improvement in the management of PTLD, the prognosis remains poor. Here we report the management of two transplanted patients with infections during immunochemotherapy (ICTH).

CASE SUMMARY
Of 65-year-old woman 11 years after kidney transplantation (first case) presented with diffuse large B-cell lymphoma (DLBCL) CS III and started ICHT according to R-CHOP protocol. Despite the secondary prevention of neutropenic fever, the patient developed grade 4 neutropenia with urinary and pulmonary tract infections after the fifth cycle. ICHT was continued in reduced doses up to 7 cycles followed by involved-field radiation therapy of the residual disease. The second case presents a 49-year-old man, 8 years after liver transplantation due to cirrhosis in the course of chronic hepatitis B, who started ICHT for DLBCL Burkitt-like CS IV. The patient received four cycles of ICHT according to R-CODOX/R-IVAC protocol, with reduced doses. In both cases initially undertaken reduction of immunosuppression was ineffective to prevent infectious complications. Despite one incomplete ICHT treatment due to recurrent infections, both our patients remain in complete remission.

CONCLUSION
Reduction of immunosuppression and the doses of chemotherapeutics may be
insufficient to prevent infectious complications during ICTH in PTLD patients.

**Key Words:** Post-transplant lymphoproliferative disease; Lymphoma; Epstein-Barr virus; Immunosuppression; Transplantation; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Post-transplant lymphoproliferative disease (PTLD) is a heterogeneous group of diseases in transplanted patients related to immunosuppression regimen, T-cell depletion and Epstein-Barr virus infection. Immunochemotherapy (ICTH) increases already high incidence of bacterial infections in transplanted patients related to the immunosuppression therapy. We report the successful management of two solid organ transplanted patients with PTLD and urinary and pulmonary tract infections during ICTH that developed regardless of the reduction of immunosuppression therapy, doses of chemotherapeutics and GCS-F used in the prevention of neutropenic fever. We show that all these interventions may be insufficient to prevent infectious complications, but they are manageable.

**Citation:** Gładyś A, Kozak S, Wdowiak K, Winder M, Chudek J. Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature. *World J Clin Cases* 2021; 9(3): 748-757

**URL:** https://www.wjgnet.com/2307-8960/full/v9/i3/748.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v9.i3.748

**INTRODUCTION**

Post-transplant lymphoproliferative disease (PTLD) is a heterogeneous group of diseases that develop after solid-organ and hematopoietic stem cells transplant$.\textsuperscript{8,9}$, 2016 WHO classification distinguished several subcategories: Plasmacytic hyperplasia, infectious mononucleosis, florid follicular hyperplasia, polymorphic (P-PTLD), monomorphic (M-PTLD) and classical Hodgkin lymphoma PTLD$.\textsuperscript{9}$ Most P-PTLD cases are EBV positive and develop shortly after transplantation. About half of M-PTLD is associated with EBV infection, and most cases are large B-cell lymphoma (DLBCL), less often Burkitt's lymphoma (BL)$\textsuperscript{10}$. The highest rate of PTLD occurs after small bowel (20%), lung (10%), and heart (6%) transplant. Liver and kidney transplantations are associated with much lower risk, accounted for 2.8% and 2.3%$\textsuperscript{11}$.

The main risk factors for PTLD are the intensity of immunosuppression regimen, T-cell depletion and Epstein-Barr virus (EBV) infection$\textsuperscript{12}$. Transplant patients who are EBV-negative before transplantation have a higher risk of PTLD. Both primary and reactivated EBV infections are potent risk factors for PTLD$\textsuperscript{13}$. The infections are often asymptomatic, with a high rate of latency$\textsuperscript{14}$.

Clinically, PTLD is hardly distinguishable from aggressive B-cell lymphoma$\textsuperscript{15}$. Immunosuppression reduction (IR) is the first step in PTLD management with overall response rate (ORR) of 45%, in the retrospective analysis$\textsuperscript{16}$. The prospective study has shown response in 1 out of 16 patients (ORR-6%)$\textsuperscript{17}$. Due to the rare occurrence of PTLD, there are currently no guidelines based on hard scientific evidence for further management of patients with PTLD.

Here we report the management of two patients with PTLD and infections during immunochemotherapy (ICTH).

**CASE PRESENTATION**

**Chief complaints**

**Case 1:** A 65-year-old woman with an extensive medical history including end-stage kidney disease, subtotal parathyroid gland removal for severe hyperparathyroidism and subtotal thyroidectomy, renal osteodystrophy, hypertension and atherosclerosis;
received a kidney transplant from a deceased donor after four years of hemodialysis therapy (2006). The donor Epstein-Barr virus (EBV) status was unknown (pre-2008 donors and recipients were not routinely screened for EBV serostatus)\(^8\). The immunosuppressive regimen consisted of mycophenolate mofetil and cyclosporine A.

**Case 2**: Forty-nine-year old man 8 years after liver transplantation for end-stage chronic hepatitis B, treated with tacrolimus and mycophenolate mofetil, was admitted to the neurological ward due to severe headache on the right side with nausea and vomiting, accompanied by the numbness of his cheek, which lasted for two weeks (October 2015). The patient reported a weight loss of 8-10 kg during the last 6 mo and presented with fever.

**History of present illness**

**Case 1**: Eleven years since transplantation (2017) the patient was referred to the transplant ward with persisting night sweats and fatigue. There was no fever and weight loss.

**Case 2**: The patient was admitted to neurological ward due to the cheek numbness. Head magnetic resonance imaging revealed the infiltration of right pterygoideus medialis muscle. He was then referred to the transplantat ward, with the suspicion of neoplastic changes. After histological examination, the patient was referred to the oncology department.

**History of past illness**

**Case 1**: The patient had a history of end-stage kidney disease with hemodialysis treatment started in 2002 and bilateral nephrectomy in 2004 followed by kidney transplantation two years later.

**Case 2**: HBV infection, which led to chronic B hepatitis and cirrhosis, followed by liver transplantation in 2006.

**Personal and family history**

**Case 1**: There was long-lasting history of hypertension. Family history was unremarkable.

**Case 2**: The patient had hypertension and reported *Helicobacter pylori* stomach infection. Family history was unremarkable.

**Physical examination**

**Case 1**: There was no lymadenopathy in physical examination. Liver and spleen were not enlarged.

**Case 2**: Physical examination revealed pleural effusion in the right cavity and symmetric ankles oedema.

**Laboratory examinations**

**Case 1**: Serologic tests for EBV were positive for IgG-class and EBNA, IgM-class was negative. The fine needle biopsy of the submandibular gland revealed monomorphic subtype of PTLD-DLBCL, the most frequent type of PTLD\(^9\). The patient was referred to the oncological ward for further diagnostic work-up. The blood tests showed leukocytosis 21.65 G/L without thrombocytopenia, mild anaemia (Hb 10.6 g/dL) increased activity of LDH (291 IU/L), and high concentration of β2-microglobulin (13.5 mg/L). The graft function was impaired (eGFR 24 mL/min/1.73m\(^2\)) without proteinuria.

**Case 2**: Histological examination of stomach biopsy gave the diagnosis of aggressive (Burkitt-like) DLBCL with CD20 (+), CD10 (+), bcl-6 (+), bcl-2 (-), MUM-1 (+/-), cyclin D1 (-), CD30 (-), CD5 (-), Ki67-almost 100%. Location of the lesions on both sides of the diaphragm in symptomatic patients (loss of weight), was corresponding to the clinical stage was IVB (IPI 3/5). HBV DNA in the blood was not detected. The patient was IgM seronegative but IgG seropositive for both cytomegalovirus (CMV) and EBV. The patients’ immunosuppression regiment was modified-mycophenolate mofetil was switched to everolimus for its anticancer properties but did not prevent DLBCL progression.
**Imaging examinations**

**Case 1:** The computed tomography (CT) examinations revealed numerous enlarged cervical, mediastinal, axillary, retroperitoneal and inguinal lymph nodes on both sides with a predominance on the left (Figure 1) as well as slight hepatosplenomegaly.

**Case 2:** CT scan of the brain was normal, while lumbar puncture revealed elevated LDL activity in cerebrospinal fluid. The patient was referred to the transplantation ward with suspicion of neoplastic infiltration. CT scan of the thorax and abdomen revealed numerous hypovascular structures in the liver and kidneys, massive infiltration of mucosa of the stomach and two nodule changes close to the left subclavian vein, below the sternocleidomastoid muscle (Figure 2).

**FINAL DIAGNOSIS**

**Case 1:** Taking into account all the symptoms and tests, a diagnosis of PLTD was made.

**Case 2:** Taking into account all the symptoms and tests, a diagnosis of PLTD was made.

**TREATMENT**

**Case 1:** The patient signed informed consent for ICTH and started R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), as initial rituximab monotherapy increases the risk of recurrence and usually does not bring complete remission in monomorphic PTLD\(^9\). Beyond slight, local upper limbs oedema, the patient tolerated the applied ICTH quite well. Night sweats subsided after the second R-CHOP cycle. Neutropenia and anaemia (requiring transient blood transfusion) were manageable. An episode of atrial fibrillation occurred after the second cycle. The immunosuppression, as well as the doses of chemotherapeutics, were reduced (mycophenolate mofetil was discontinued) due to episodes of prolonged pancytopenia. The G-CSF treatment (filgrastim) in the secondary prevention of neutropenic fever (NF) was used. Regardless of the use of GCS-F and Pneumocystis jiroveci prophylaxis (with co-trimoxazole), after the fifth cycle, the patient developed grade 4 neutropenia with symptoms of febrile neutropenia. There was an increase in the concentration of inflammatory markers: CRP 217 mg/L and procalcitonin 40.1 ng/mL. Empirical antibiotic therapy with ciprofloxacin was started. After one week, regardless of neutrophil recovery, inflammatory parameters were still elevated and the symptoms (fever, weakness, and dysuria) persisted. Blood culture showed a growth of Staphylococcus aureus (sensitive to ciprofloxacin) and Klebsiella pneumoniae ESBL (+) (resistant to ciprofloxacin and co-trimoxazole, but sensitive to carbapenems and aminoglycosides). Broad-spectrum antibiotic therapy with meropenem (1 g for every 12 h) and amikacin (500 mg once a day) was administered. Three days later, there was a worsening of dyspnea, cough and decreased oxygen saturation of 88%-90%, without an increase in the concentration of inflammatory markers. Pneumocystis jiroveci infection was suspected and a smear from the epiglottis was taken for the examination. Additionally, co-trimoxazole was administered intravenously at a dose of 960 mg twice daily. Few days later, a significant improvement of the patient's clinical condition with a decrease of inflammatory markers concentration (CRP 14.8 mg/L and PCT 0.4 ng/mL) was observed. The patient recovered, however with persisting impaired graft function. The doses of ICTH were reduced by 30% in the next 2 cycles. Despite dose reduction, the therapy had been terminated because of grade 4 neutropenia.

PET-CT performed after the seventh cycle revealed active lesions in sub- and infraclavicular area with the avidity of 4 points in the Deauville five-point scale. The patient started involved-field radiation therapy (3D-IMRT, Dc = 30 Gy/df = 3) of the residual disease.

**Case 2:** The patient signed informed consent for ICTH with 4 cycles of R-CODOX (rituximab, cyclophosphamide doxorubicin, vincristine, cytarabine) followed by R-IVAC scheme (rituximab, ifosfamide, cytarabine, methotrexate) and started the treatment. After the 1st cycle of R-CODOX therapy, symptoms of neutropenic fever appeared. The presence of multi-drug-resistant bacteria was found in the blood...
The first blood culture revealed Stenotrophomonas maltophilia and ESBL Escherichia coli (resistant to beta-lactams, cephalosporins and co-trimoxazole but sensitive to carbapenems) and 5 d later the second blood culture showed MRCNS Staphylococcus lentus and MRCNS Staphylococcus hominis (resistant to beta-lactams, carbapenems, cephalosporins but sensitive to aminoglycosides). CRP level was 164 mg/L. After therapy with meropenem (1 g every 8 h) and amicin (500 mg daily) for ten days, CRP level decreased to 6.0 mg/L. Subsequently, ICTH was continued with reduced doses and after the second R-IVAC cycle, neutropenia developed with negative blood cultures (performed 3 times). Because of the clinical symptoms (fever, dyspnoea, weakness) and high CRP level 173 ng/mL intravenous therapy with vancomycin (2 g every 8 h) was started. As there was no clinical improvement (repeated negative blood cultures), after 7 d, colistin was administered intravenously (2 mL units every 8 h) with a good clinical response (CRP 15.8 mg/L). During the whole ICTH the patient received red blood cells transfusions (14 units in total) because of grade 4 anaemia.
OUTCOME AND FOLLOW-UP

Case 1: The treatment was complicated by neutropenia and anemia, but followed by complete remission (CR). After two years the patient remains in CR with stable, however poor allograft function (eGFR 21.8 mL/min/1.73 m²). The patient remains under the care of an oncologist and a clinical transplantologist. The timeline of the information presented in this case report is presented in Table 1.

Case 2: ICHT was complicated by neutropenia and anemia, but followed by CR in CT scans of the neck, thorax, abdomen and pelvis as well as trephine biopsy (March 2016). After 4 years the patient remains in CR with regular check-up every 6 mo in the oncology outpatient clinic. Table 2 presents the information from this case report organized into a timeline.

DISCUSSION

According to 2019 NCCN guidelines[1], the first-line treatment always includes the reduction of immunosuppressive drug regime. Further management depends on PTLD subtype and patient’s response to changes in the immunosuppression. In both reported cases the reduction of immunosuppression regimen was ineffective, however safe, and was not followed by acute rejection or progressive deterioration in graft function[1]. Currently, the standard of care in case of this type of lymphomas is the initial administration of rituximab as monotherapy and depending on the response to treatment, its continuation or the implementation of CHOP chemotherapy[2-10]. These recommendations are based on the results of the largest prospective study so far—PTLD-1. According to this trial, about 25% of PTLD patients may not require chemotherapy[11]. Also, after sequential therapy low treatment mortality rate was observed (13%) in comparison to upfront CHOP chemotherapy (26%) described in the literature[12]. Because of the fast progression of the disease and no response to IR we decided to start ICHT upfront but with reduced doses. Besides single-centre experience reports, there is no clinical trial with BL after solid organ transplantation. The role of CNS prophylaxis is unclear.

Despite the immunosuppression therapy reduction, both our patients developed severe infections during ICHT. Immunosuppression therapy in transplanted patients per se is associated with an increased incidence of bacterial infections of the urinary and respiratory tracts. Urinary tract infections were reported to occur almost twice more frequently than in non-transplant patients (7% vs 4.4%)[13]. The occurrence of pneumonia depends on transplanted organs and ranges from 7.3% in the kidney[14], 22% in the liver[15], up to 36% in the lung graft recipients[16] during the first post-transplant year. Infectious complications in kidney transplant patients are associated with significant morbidity and mortality[17], highest in developing countries associated with low socioeconomic profile[18,19], and severity of immunosuppression regimen[20]. Prophylactic use of antibiotics decreased the prevalence from 6.3% to 2.2% at the end of the first year after transplantation[21]. Trappe et al[22] noticed grade 3 and grade 4 infections in about 41% of patients and grade 3 and grade 4 leukopenia in 68% of patients during PTLD chemotherapy[23].

Neutropenic fever is a common adverse event during R-CHOP treatment of DLBCL with the incidence estimated at 5%-40%[24,25], usually occurring after the first cycle of ICHT[26]. There is no data on the frequency of NF in PTLD patients. Our kidney transplant patient presented with NF in the fifth cycle despite using G-CSF prophylaxis, which is a standard in NF prevention[27]. NF was successfully treated with antibiotics, however, associated with deterioration of the kidney graft function.

We confirm that Pneumocystis carinii prophylaxis should be utilized in each PTLD patients during ICHT and consisted of 960 mg co-trimoxazole orally 3 times a week[28]. The prophylaxis is recommended as the infection occurs in one-third of treated PTLD patients[29].

Despite the improvement in the management of PTLD, related mainly to the introduction of rituximab in B-cell lymphoproliferative disorders[27], the prognosis remains generally poor[29-31], with 55% 3-year overall survival[1], median OS 64 mo[32]. Until now both our patients remain in clinical remission, despite one of the patients had not received complete ICHT treatment due to recurrent infections.

It is worth to be mentioned that PTLD may be linked to other viruses presence, such as HCV, HHV-8 and CMV[7]. Although it has been reported that after liver transplant, HBV reactivation plays an important role in PTLD occurrence[30,31], even 12 years after transplantation[31]. In the case of our patient, the disease onset was late (8 years after
Table 1 Timeline of the diagnostic procedures and treatment of the first case

<table>
<thead>
<tr>
<th>Date</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 1, 2002</td>
<td>Dialysis initiation</td>
</tr>
<tr>
<td>August 2, 2004</td>
<td>Laparotomy with bilateral nephrectomy</td>
</tr>
<tr>
<td>July 18, 2006</td>
<td>Kidney transplantation</td>
</tr>
<tr>
<td>October 5, 2006</td>
<td>Thyroid and parathyroid resection</td>
</tr>
<tr>
<td>July 28 to August 10, 2017</td>
<td>Hospital stay at the nephrology ward</td>
</tr>
<tr>
<td>July 31, 2017</td>
<td>Retrieval of the submandibular node</td>
</tr>
<tr>
<td>August 7, 2017</td>
<td>Chest CT scan</td>
</tr>
<tr>
<td>August 28 to September 8, 2017</td>
<td>1&lt;sup&gt;st&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>August 31, 2017</td>
<td>Abdominal CT scan</td>
</tr>
<tr>
<td>September 4 and 5, 2017</td>
<td>Chemotherapy I</td>
</tr>
<tr>
<td>September 25 to October 9, 2017</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>September 25 and 26, 2017</td>
<td>Chemotherapy II</td>
</tr>
<tr>
<td>September 29, 2017</td>
<td>Blood transfusion-2 units</td>
</tr>
<tr>
<td>October 16 to 25, 2017</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>October 18 and 19, 2017</td>
<td>Chemotherapy III</td>
</tr>
<tr>
<td>October 19, 2017</td>
<td>Abdominal CT scan</td>
</tr>
<tr>
<td>November 8 to 24, 2017</td>
<td>4&lt;sup&gt;th&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>October 8 and November 8, 2017</td>
<td>Chemotherapy IV</td>
</tr>
<tr>
<td>November 11, 2017</td>
<td>Chest CT scan</td>
</tr>
<tr>
<td>December 15, 2017 to January 24, 2018</td>
<td>5&lt;sup&gt;th&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>December 15 and 16, 2017</td>
<td>Chemotherapy V</td>
</tr>
<tr>
<td>January 23, 2018</td>
<td>Chemotherapy VI</td>
</tr>
<tr>
<td>February 28 to March 7, 2018</td>
<td>6&lt;sup&gt;th&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>March 1, 2018</td>
<td>Chemotherapy VII</td>
</tr>
<tr>
<td>April 10, 2018</td>
<td>Positron emission tomography (PET scan)</td>
</tr>
<tr>
<td>April 12 to 27, 2018</td>
<td>7&lt;sup&gt;th&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
<tr>
<td>June 28 to July 11, 2018</td>
<td>Radiation therapy</td>
</tr>
<tr>
<td>July 12 to 17, 2018</td>
<td>8&lt;sup&gt;th&lt;/sup&gt; hospital stay at the oncology department</td>
</tr>
</tbody>
</table>

CT: Computed tomography; PET: Positron emission computed tomography.

liver transplant), and the patient HBV DNA remains undetectable, therefore the PTLD (DLBCL) seems unrelated to hepatotropic viruses.

**CONCLUSION**

In summary, ICTH on the tope of immunosuppression therapy increases the risk of infectious complications in PTLD patients. Reduction of immunosuppression and the doses of chemotherapeutics may be insufficient to diminish the risk of infectious complications during ICTH.
Table 2 Timeline of the diagnostic procedures and treatment of the second case

<table>
<thead>
<tr>
<th>Date</th>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>Liver transplantation</td>
</tr>
<tr>
<td>October 24, 2015</td>
<td>Head CT scan</td>
</tr>
<tr>
<td>October 24, 2015</td>
<td>Lumbar puncture</td>
</tr>
<tr>
<td>October 26, 2015</td>
<td>Head MRI scan</td>
</tr>
<tr>
<td>October 27, 2015</td>
<td>Discharge from the neurological ward</td>
</tr>
<tr>
<td>October 27 to November 9, 2015</td>
<td>Hospital stay at the transplantation ward</td>
</tr>
<tr>
<td>October 29, 2015</td>
<td>Chest CT scan</td>
</tr>
<tr>
<td>November 3, 2015</td>
<td>Stomach biopsy</td>
</tr>
<tr>
<td>November 9, 2015 to March 14, 2016</td>
<td>Hospital stay at the oncology department</td>
</tr>
<tr>
<td>November 10, 2015 to February 18, 2016</td>
<td>Chemotherapy</td>
</tr>
<tr>
<td>March 9, 2016</td>
<td>Chest CT scan</td>
</tr>
<tr>
<td>March 11, 2016</td>
<td>Trephine biopsy</td>
</tr>
</tbody>
</table>

CT: Computed tomography; MRI: Magnetic resonance imaging.

REFERENCES


Gladyś A et al. Infectious complications during ICTH of PTLD

